Managers / Q1 2022 · view latest →
ISZO CAPITAL MANAGEMENT LP
CIK 0001607925 · 590 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10022 · 646-775-4394
Summary
Iszo Capital Management LP reported $84M in U.S.-listed holdings across 5 positions for Q1 2022.
The portfolio is heavily concentrated: Nam Tai Ppty alone accounts for 53.5% of reported value.
Compared with Q4 2021, the fund opened 1 new position and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 53.5% · $45M
- Common Stock · 41.4% · $35M
- REIT · 5.1% · $4M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CBLCBL & ASSOC PPTYS INC | NEW | +131.1K | 131.1K | +$4M | $4M |
| AVID BIOSERVICES INC | SOLD OUT | −2.21M | 0 | −$64M | $0 |
| XPELXPEL INC | SOLD OUT | −103.9K | 0 | −$7M | $0 |
| GLOBAL CORD BLOOD CORPORATIO | SOLD OUT | −1.0K | 0 | −$4,000 | $0 |
| NOTVQINOTIV INC | TRIMMED | −1.01M | 264.6K | −$28M | $25M |
| CCELCRYO-CELL INTL INC | TRIMMED | −125.8K | 357.1K | −$3M | $3M |
| LFCRLANDEC CORP | ADDED | +251.6K | 2.18M | −$14M | $7M |
| NAM TAI PPTY INC | ADDED | +546.0K | 7.22M | +$7M | $45M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | NAM TAI PPTY INC | SHS | 53.53% | $45M | 7.22M |
| 2 | NOTVQINOTIV INChistory → | COM | 29.91% | $25M | 264.6K |
| 3 | LFCRLANDEC CORPhistory → | COM | 8.22% | $7M | 2.18M |
| 4 | CBLCBL & ASSOC PPTYS INChistory → | COMMON STOCK | 5.12% | $4M | 131.1K |
| 5 | CCELCRYO-CELL INTL INChistory → | COM | 3.23% | $3M | 357.1K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2023 | $2M | 1 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $2M | 3 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $18M | 3 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $19M | 10 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $7M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $58M | 6 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $64M | 6 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $84M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $190M | 7 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $227M | 7 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $275M | 8 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $212M | 5 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $96M | 6 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $74M | 5 | Nov 17, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $57M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $65M | 10 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $69M | 3 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $76M | 4 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $64M | 2 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $61M | 5 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $92M | 5 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.